Trodelvy (sacituzumab govitecan‑hziy) combined with Keytruda (pembrolizumab) produced a 35 % reduction in the risk of disease progression or death in patients with first‑line, PD‑L1‑positive metastatic triple‑negative breast cancer, as reported in the New England Journal of Medicine. The hazard ratio of 0.65 (p < 0.001) translates into a median progression‑free survival of 11.2 months for the combination versus 7.8 months for Keytruda plus chemotherapy.
The result establishes Trodelvy plus Keytruda as a potential new standard of care in a setting that has historically relied on chemotherapy alone. By moving the drug into the first‑line position, Gilead expands the addressable market beyond the current second‑line and HR⁺/HER2⁻ indications, positioning the ADC to capture a larger share of the aggressive triple‑negative breast cancer population.
Commercially, Trodelvy sales grew 24 % to $1.3 billion in 2024, but Q1 2025 sales fell 5 % to $293 million due to pricing adjustments and inventory realignments. The positive clinical data are expected to offset these headwinds, support the supplemental regulatory submissions, and provide a stronger foundation for future revenue growth as the drug moves into earlier lines of therapy.
Chief Medical Officer Dietmar Berger said the findings “represent important progress toward delivering Trodelvy to patients in earlier lines of breast cancer treatment, with potential to become a backbone therapy for all frontline metastatic TNBC patients.” Principal Investigator Sara Tolaney added that the combination “is a meaningful step forward in establishing a potential new standard of care for this challenging disease.”
Gilead has submitted supplemental applications to the U.S. Food and Drug Administration and the European Medicines Agency for the first‑line indication. The market has responded positively, with investors noting the commercial upside and analysts raising their outlooks for the oncology segment.
The competitive landscape includes other antibody‑drug conjugates and chemotherapy‑immunotherapy combinations. ASCENT‑03 had already shown a 38 % risk reduction with Trodelvy monotherapy in patients not eligible for PD‑1/PD‑L1 inhibitors, reinforcing the drug’s efficacy profile. The new data strengthen Trodelvy’s positioning as a first‑line option and may accelerate its adoption in clinical practice.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.